Skip to navigation bar Skip to breadcrumbs Skip to page content
Envelope icon E-mail Updates Teal square Text size:  a A A

Aspirin for the Prevention of Cardiovascular Disease: Preventive Medication

Release Date: March 2009

This topic is in the process of being updated. Please go to the Update in Progress section to see the latest documents available.

Recommendation Summary

Summary of Recommendations and Evidence

PopulationRecommendationGrade
(What's This?)
Men, Age 45-79
The USPSTF recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage. See the Clinical Considerations section for discussion of benefits and harms. 
The USPSTF recommends the service. There is high certainty that the net benefit is substantial.
Women, Age 55-79
The USPSTF recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage. See the Clinical Considerations section for discussion of benefits and harms.
The USPSTF recommends the service. There is high certainty that the net benefit is substantial.
Men and Women, 80 Years and Older
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of aspirin for cardiovascular disease prevention in men and women 80 years or older. See the Clinical Considerations section for suggestions for practice regarding the I statement.
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.
Women Younger than 55 (Stroke), Men Younger than 45 (MI)
The USPSTF recommends against the use of aspirin for stroke prevention in women younger than 55 years and for myocardial infarction prevention in men younger than 45 years.
The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits

Go to the Clinical Considerations section for suggestions for practice when the evidence is insufficient.

Clinical Summary

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice.

This summary is intended for use by primary care clinicians.

 
Current as of: September 2013

Internet Citation: Recommendation Summary. U.S. Preventive Services Task Force. September 2014.
http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/aspirin-for-the-prevention-of-cardiovascular-disease-preventive-medication

USPSTF Program Office   540 Gaither Road, Rockville, MD 20850